{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T19:58:10Z","timestamp":1782417490926,"version":"3.54.5"},"reference-count":29,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T00:00:00Z","timestamp":1750636800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Genet."],"abstract":"<jats:p>Glycogen storage disease II or Pompe disease (PD), is a rare autosomal recessive disorder due to biallelic pathogenic variants in <jats:italic>GAA<\/jats:italic>, resulting in the enzymatic deficiency of alpha-1,4-glucosidase. Two clinical forms are recognized, namely, early onset (EOPD) and late-onset (LOPD). We present the case of an asymptomatic 33-year-old man who underwent a genetic screening for autosomal recessive disorders (parental prenatal counselling) and was found to carry the homozygous pathogenic <jats:italic>GAA<\/jats:italic> substitution NM_000152.5(GAA):c.-32-13T&amp;gt;G (IVS1). Neurological examination, serum CK levels, electromyography, muscle MRI, respiratory and cardiac screening were reported normal. We investigated the effects of the variant at transcript and protein levels in available tissues from the proband and his parents. The IVS1-32-13T&amp;gt;G variant (dbSNP: rs386834236, Clin Var ID: 4,027) occurs in 90% of Caucasian LOPD patients and is associated with a broad range of symptom onset. About 50 subjects have been reported harboring this variant in homozygosis and most of them are asymptomatic, although a subset develops symptoms with time. Residual levels of alpha-1,4-glucosidase activity and protein content do not seem to reflect clinical severity in homozygous IVS1 LOPD patients.<\/jats:p>","DOI":"10.3389\/fgene.2025.1574381","type":"journal-article","created":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T05:21:34Z","timestamp":1750656094000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Case Report: Incidental late-onset Pompe disease diagnosis in a man with no clinical and instrumental evidence of neuromuscular dysfunction"],"prefix":"10.3389","volume":"16","author":[{"given":"Monica","family":"Sciacco","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"Lucchiari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Letizia","family":"Bertolasi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giacomo Pietro","family":"Comi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Corti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dario","family":"Ronchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,6,23]]},"reference":[{"key":"B1","first-page":"497","article-title":"Clinical guidelines for late-onset Pompe disease","volume":"54","author":"Barba-Romero","year":"2012","journal-title":"Rev. Neurol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1016\/j.ebiom.2019.03.048","article-title":"A genetic modifier of symptom onset in Pompe disease","volume":"43","author":"Bergsma","year":"2019","journal-title":"EBioMedicine"},{"key":"B3","first-page":"887","article-title":"Leaky splicing mutation in the acid maltase gene is associated with delayed onset of glycogenosis type II","volume":"56","author":"Boerkoel","year":"1995","journal-title":"Am. J. Hum. Genet."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1093\/nar\/gkt987","article-title":"Functional characterization of the common c.-32-13T>G mutation of GAA gene: identification of potential therapeutic agents","volume":"42","author":"Dardis","year":"2013","journal-title":"Nucleic Acids Res."},{"key":"B5","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1002\/mus.24653","article-title":"SHOULD patients with asymptomatic pompe disease be treated? A nationwide study in France","volume":"51","author":"Echaniz-Laguna","year":"2015","journal-title":"Muscle Nerve"},{"key":"B6","doi-asserted-by":"publisher","first-page":"362","DOI":"10.3390\/genes14020362","article-title":"Treatment dilemma in children with late-onset pompe disease","volume":"14","author":"Faraguna","year":"2023","journal-title":"Genes (Basel)"},{"key":"B7","doi-asserted-by":"publisher","first-page":"507","DOI":"10.3390\/life11060507","article-title":"Correlation of GAA genotype and acid-\u03b1-glucosidase enzyme activity in Hungarian patients with pompe disease","volume":"11","author":"Gal","year":"2021","journal-title":"Life"},{"key":"B8","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1016\/j.ymthe.2017.05.019","article-title":"Glycogen reduction in myotubes of late-onset pompe disease patients using antisense technology","volume":"25","author":"Goina","year":"2017","journal-title":"Mol. Ther."},{"key":"B9","doi-asserted-by":"publisher","first-page":"100929","DOI":"10.1016\/j.ymgmr.2022.100929","article-title":"Newborn screening for Pompe disease in Italy: long-term results and future challenges","volume":"33","author":"Gragnaniello","year":"2022","journal-title":"Mol. Genet. Metab. Rep."},{"key":"B10","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.1093\/hmg\/3.12.2231","article-title":"Aberrant splicing in adult onset glycogen storage disease type II (GSDII): molecular identification of an IVS1 (\u2013 13T\u2192G) mutation in a majority of patients and a novel IVS10 (+1GT \u2192 CT) mutation","volume":"3","author":"Hule","year":"1994","journal-title":"Hum. Mol. Genet."},{"key":"B11","doi-asserted-by":"publisher","first-page":"2431","DOI":"10.1002\/ajmg.a.36110","article-title":"Timing of diagnosis of patients with pompe disease: data from the pompe registry","volume":"161","author":"Kishnani","year":"2013","journal-title":"Am. J. Med. Genet. A"},{"key":"B12","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s13023-016-0390-6","article-title":"Diagnosis of late-onset Pompe disease and other muscle disorders by next-generation sequencing","volume":"11","author":"L\u00e9vesque","year":"2016","journal-title":"Orphanet J. Rare Dis."},{"key":"B13","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1212\/wnl.27.2.178","article-title":"Residual acid maltase activity in late-onset acid maltase deficiency","volume":"27","author":"Mehler","year":"1977","journal-title":"Neurology"},{"key":"B14","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1016\/j.nmd.2007.06.002","article-title":"Late onset Pompe disease: clinical and neurophysiological spectrum of 38 patients including long-term follow-up in 18 patients","volume":"17","author":"M\u00fcller-Felber","year":"2007","journal-title":"Neuromuscul. Disord. NMD"},{"key":"B15","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/j.nmd.2015.07.002","article-title":"Homozygosity for the common GAA gene splice site mutation c.-32-13T>G in Pompe disease is associated with the classical adult phenotypical spectrum","volume":"25","author":"Musumeci","year":"2015","journal-title":"Neuromuscul. Disord."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1954","DOI":"10.1002\/humu.23854","article-title":"Extension of the Pompe mutation database by linking disease\u2010associated variants to clinical severity","volume":"40","author":"Ni\u00f1o","year":"2019","journal-title":"Hum. Mutat."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1002\/humu.24272","article-title":"Broad variation in phenotypes for common GAA genotypes in Pompe disease","volume":"42","author":"Ni\u00f1o","year":"","journal-title":"Hum. Mutat."},{"key":"B18","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1038\/s41431-020-00752-2","article-title":"Enzymatic diagnosis of Pompe disease: lessons from 28 years of experience","volume":"29","author":"Ni\u00f1o","year":"","journal-title":"Eur. J. Hum. Genet."},{"key":"B19","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1186\/s13023-024-03373-w","article-title":"The European reference network for metabolic diseases (MetabERN) clinical pathway recommendations for Pompe disease (acid maltase deficiency, glycogen storage disease type II)","volume":"19","author":"Parenti","year":"2024","journal-title":"Orphanet J. Rare Dis."},{"key":"B20","doi-asserted-by":"publisher","first-page":"278","DOI":"10.21037\/atm.2019.04.13","article-title":"Molecular genetics of Pompe disease: a comprehensive overview","volume":"7","author":"Peruzzo","year":"2019","journal-title":"Ann. Transl. Med."},{"key":"B21","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.ymgme.2017.09.008","article-title":"Insight into the phenotype of infants with Pompe disease identified by newborn screening with the common c.-32-13T>G \u201clate-onset\u201d GAA variant","volume":"122","author":"Rairikar","year":"2017","journal-title":"Mol. Genet. Metab."},{"key":"B22","doi-asserted-by":"publisher","first-page":"2146","DOI":"10.1002\/humu.23878","article-title":"GAA variants and phenotypes among 1,079 patients with Pompe disease: data from the Pompe Registry","volume":"40","author":"Reuser","year":"2019","journal-title":"Hum. Mutat."},{"key":"B23","doi-asserted-by":"publisher","first-page":"31","DOI":"10.3390\/ijns6020031","article-title":"Newborn screening for pompe disease","volume":"6","author":"Sawada","year":"2020","journal-title":"Int. J. Neonatal Screen"},{"key":"B24","doi-asserted-by":"publisher","first-page":"101085","DOI":"10.1016\/j.ymgmr.2024.101085","article-title":"Acid \u03b1-glucosidase (GAA) activity and glycogen content in muscle biopsy specimens of patients with Pompe disease: a systematic review","volume":"39","author":"Schoser","year":"2024","journal-title":"Mol. Genet. Metab. Rep."},{"key":"B25","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1111\/j.1365-2990.2007.00839.x","article-title":"Adult-onset glycogen storage disease type 2: clinico-pathological phenotype revisited","volume":"33","author":"Schoser","year":"2007","journal-title":"Neuropathol. Appl. Neurobiol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/s00401-005-1026-4","article-title":"Delayed or late-onset type II glycogenosis with globular inclusions","volume":"110","author":"Sharma","year":"2005","journal-title":"Acta Neuropathol. Berl."},{"key":"B27","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1007\/s11940-022-00736-1","article-title":"Pompe disease: a clinical, diagnostic, and therapeutic overview","volume":"24","author":"Stevens","year":"2022","journal-title":"Curr. Treat. Options Neurol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.omtn.2017.03.002","article-title":"GAA deficiency in pompe disease is alleviated by exon inclusion in iPSC-derived skeletal muscle cells","volume":"7","author":"Wal","year":"","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"B29","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.omtn.2017.03.001","article-title":"Antisense oligonucleotides promote exon inclusion and correct the common c.-32-13t>G GAA splicing variant in pompe disease","volume":"7","author":"Wal","year":"","journal-title":"Mol. Ther. Nucleic Acids"}],"container-title":["Frontiers in Genetics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fgene.2025.1574381\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T05:21:36Z","timestamp":1750656096000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fgene.2025.1574381\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,23]]},"references-count":29,"alternative-id":["10.3389\/fgene.2025.1574381"],"URL":"https:\/\/doi.org\/10.3389\/fgene.2025.1574381","relation":{},"ISSN":["1664-8021"],"issn-type":[{"value":"1664-8021","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,23]]},"article-number":"1574381"}}